DMK Pharmaceuticals CorpOTC Pink - Limited Information:DMKPQ
- LAST PRICE0.0350
- TODAY'S CHANGE (%)-0.0010 (-2.7778%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0416 / 0.0360
- Day Range
- 52 Week Range
- Volume143,836
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DMKPQ |
|---|---|---|
| 09:41 ET | 100 | 0.0416 |
| 10:32 ET | 100 | 0.036 |
| 11:02 ET | 9995 | 0.04 |
| 12:14 ET | 4962 | 0.04 |
| 12:20 ET | 116000 | 0.035 |
| 12:48 ET | 11231 | 0.036 |
| 02:36 ET | 940 | 0.0496 |
| 03:03 ET | 100 | 0.035 |
| 03:54 ET | 100 | 0.035 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DMK Pharmaceuticals Corp | 353.6K | 0.0x | --- |
Procyon Corp | 1.6M | -5.1x | --- |
Evoke Pharma Inc | 3.9M | -0.2x | --- |
Akanda Corp | 1.2M | 0.0x | --- |
Biostar Pharmaceuticals Inc | 260.0 | 0.0x | --- |
Aaron Sparks Industries Inc | 4.1K | 0.0x | --- |
Company Information
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Contact Information
- Headquarters
- 11682 El Camino Real, Suite 300SAN DIEGO, CA, United States 92130
- Phone
- 858-997-2400
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Ebrahim Versi
- Chief Financial Officer
- Seth Cohen
- General Counsel, Company Secretary
- John Dorbin
- Director
- Jannine Versi
- Independent Director
- Howard Birndorf
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $353.6K |
|---|---|
Revenue (TTM) | $3.6M |
Shares Outstanding | 10.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-8.69 |
Book Value | $-0.30 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -685.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
